Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: COCP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.84% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.16M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 1.13 | 52 Weeks Range 0.90 - 2.44 | Updated Date 01/8/2026 |
52 Weeks Range 0.90 - 2.44 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.77% | Return on Equity (TTM) -94.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9016471 | Price to Sales(TTM) 92.45 |
Enterprise Value 9016471 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 13782372 | Shares Floating 9191628 |
Shares Outstanding 13782372 | Shares Floating 9191628 | ||
Percent Insiders 32.48 | Percent Institutions 4.83 |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma, Inc. was founded in 2000 and has focused on developing novel antiviral therapeutics. The company has undergone several strategic shifts and partnerships throughout its history, aiming to advance its pipeline of drug candidates.
Core Business Areas
- Antiviral Therapeutics Development: Cocrystal Pharma is primarily engaged in the discovery, development, and commercialization of orally administered antiviral drugs. Their focus is on developing treatments for significant viral diseases that lack effective therapies.
Leadership and Structure
The leadership team and organizational structure of Cocrystal Pharma can be found in their official investor relations materials and SEC filings. Key personnel typically include a CEO, CFO, CSO, and a Board of Directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Product Name 1: Cocrystal Pharma has a pipeline of drug candidates rather than fully commercialized products. Their lead candidates are focused on treating Hepatitis C virus (HCV) and potentially other viral infections. Specific market share data for these investigational drugs is not applicable as they are not yet approved or marketed. Competitors in the HCV space include Gilead Sciences (Sovaldi, Harvoni), AbbVie (Mavyret), and Bristol Myers Squibb (Sunveka).
Market Dynamics
Industry Overview
The antiviral therapeutics market is a dynamic and significant sector within the pharmaceutical industry, driven by the continuous emergence of new viral threats and the need for effective treatments for existing viral diseases. The market is characterized by high R&D investment, stringent regulatory processes, and intense competition.
Positioning
Cocrystal Pharma positions itself as a developer of innovative, orally available antiviral drugs with the potential to address unmet medical needs. Their competitive advantage lies in their proprietary drug discovery platform and their focus on specific viral targets.
Total Addressable Market (TAM)
The total addressable market for antiviral therapeutics is substantial and growing, encompassing treatments for a wide range of viral infections. Cocrystal Pharma's positioning within this TAM is dependent on the successful development and regulatory approval of their pipeline candidates, targeting specific niches within the broader antiviral market.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform focused on antivirals.
- Pipeline of novel antiviral drug candidates targeting significant viral diseases.
- Focus on orally administered drugs, which often offer patient convenience.
Weaknesses
- Early-stage development of most pipeline candidates.
- Reliance on external funding and partnerships for continued development.
- Limited commercialization experience as a smaller biotech company.
Opportunities
- Increasing global demand for effective antiviral treatments.
- Potential for strategic partnerships and licensing agreements.
- Development of treatments for emerging or neglected viral diseases.
Threats
- High risk and cost associated with drug development and clinical trials.
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Potential for unexpected safety or efficacy issues during development.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
Competitive Landscape
Cocrystal Pharma faces significant competition from established pharmaceutical giants with larger R&D budgets, extensive clinical trial experience, and existing commercial infrastructure. Their advantages lie in their potentially novel mechanisms of action and focus on specific unmet needs, but they must overcome the substantial resource disparities.
Growth Trajectory and Initiatives
Historical Growth: Historically, Cocrystal Pharma's growth trajectory has been characterized by R&D advancements, pipeline progression, and strategic partnerships rather than revenue growth. Milestones have included the initiation of clinical trials and the advancement of drug candidates through different phases.
Future Projections: Future projections for Cocrystal Pharma are heavily dependent on the successful clinical development and regulatory approval of its lead drug candidates. Analyst estimates, if available, would focus on potential market penetration and revenue once products are commercialized.
Recent Initiatives: Recent initiatives have likely focused on advancing their clinical programs, securing funding, and potentially exploring new therapeutic areas or collaborations. Specific initiatives would be detailed in company press releases and SEC filings.
Summary
Cocrystal Pharma is a clinical-stage biotechnology company focused on developing novel antiviral therapies. While possessing promising pipeline candidates and proprietary technology, its primary challenges lie in the high-risk, high-cost nature of drug development and intense competition. Success hinges on navigating clinical trials and regulatory approvals, necessitating strategic partnerships and robust funding to realize its growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Research Reports
- Company Investor Relations Website
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data may be subject to change and may not be exhaustive. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cocrystalpharma.com |
Full time employees 11 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.